Key Points
- Insider sold: Director Luke Thomas Power sold 62,250 shares at an average price of $26.58 for proceeds of $1,654,605, reducing his stake by 38.47% to 99,571 shares; the transaction was disclosed in an SEC Form 4 filing.
- Analyst sentiment is cautious: Several brokers have cut or issued holds on CAI (Weiss Ratings: sell; Wall Street Zen: buy→hold; Canaccord: hold) and MarketBeat shows an average rating of "Reduce" with a $28 average target while the stock trades near $26.76 (12‑month range $22.86–$42.50).
Caris Life Sciences, Inc. (NASDAQ:CAI - Get Free Report) insider Luke Thomas Power sold 62,250 shares of the firm's stock in a transaction dated Thursday, December 11th. The stock was sold at an average price of $26.58, for a total transaction of $1,654,605.00. Following the transaction, the insider directly owned 99,571 shares of the company's stock, valued at $2,646,597.18. The trade was a 38.47% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website.
Caris Life Sciences Stock Up 0.8%
NASDAQ CAI opened at $26.76 on Friday. Caris Life Sciences, Inc. has a twelve month low of $22.86 and a twelve month high of $42.50.
Analysts Set New Price Targets
A number of brokerages have recently issued reports on CAI. Weiss Ratings reissued a "sell (d)" rating on shares of Caris Life Sciences in a report on Wednesday. Wall Street Zen cut Caris Life Sciences from a "buy" rating to a "hold" rating in a research report on Saturday, December 6th. Finally, Canaccord Genuity Group began coverage on Caris Life Sciences in a report on Tuesday, December 2nd. They set a "hold" rating and a $28.00 price objective for the company. One analyst has rated the stock with a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, the stock presently has an average rating of "Reduce" and an average target price of $28.00.
Read Our Latest Research Report on CAI
About Caris Life Sciences
(
Get Free Report)
We are a leading, patient-centric, next-generation AI TechBio company and precision medicine pioneer. We develop and commercialize innovative solutions to transform healthcare through the use of comprehensive molecular information and artificial intelligence/machine learning algorithms at scale. Our entire portfolio of precision medicine solutions is designed to benefit patients, with an initial focus on oncology, and serves the clinical, academic, and biopharma markets.
Featured Stories
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
